China Pharma Holdings Stock Cash Per Share
| CPHI Stock | USD 0.20 0.01 5.26% |
China Pharma Holdings fundamentals help investors to digest information that contributes to China Pharma's financial success or failures. It also enables traders to predict the movement of China Stock. The fundamental analysis module provides a way to measure China Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China Pharma stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 0.44 | 0.51 |
China | Cash Per Share |
China Pharma Holdings Company Cash Per Share Analysis
China Pharma's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current China Pharma Cash Per Share | 0.04 X |
Most of China Pharma's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China Pharma Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
China Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for China Pharma is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Cash Per Share. Since China Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
China Cash Per Share Historical Pattern
Today, most investors in China Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various China Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of China Pharma cash per share as a starting point in their analysis.
China Pharma Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
China Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, China Pharma Holdings has a Cash Per Share of 0.04 times. This is 99.08% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash per share for all United States stocks is 99.2% higher than that of the company.
China Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China Pharma's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China Pharma could also be used in its relative valuation, which is a method of valuing China Pharma by comparing valuation metrics of similar companies.China Pharma is currently under evaluation in cash per share category among its peers.
China Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of China Pharma from analyzing China Pharma's financial statements. These drivers represent accounts that assess China Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of China Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 51.6M | 97.2M | 111.3M | 2.0M | 2.4M | 2.2M | |
| Enterprise Value | 55.1M | 103.7M | 118.9M | 5.3M | 6.0M | 5.7M |
China Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (0.70) % | ||||
| Operating Margin | (1.50) % | ||||
| Current Valuation | 8.8 M | ||||
| Shares Outstanding | 19.25 M | ||||
| Shares Owned By Insiders | 51.27 % | ||||
| Shares Owned By Institutions | 0.21 % | ||||
| Number Of Shares Shorted | 93.6 K | ||||
| Price To Earning | (0.89) X | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.01 M | ||||
| Gross Profit | 349.27 K | ||||
| EBITDA | 8.44 K | ||||
| Net Income | (3.08 M) | ||||
| Cash And Equivalents | 2.24 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 4.63 M | ||||
| Debt To Equity | 2.62 % | ||||
| Current Ratio | 0.75 X | ||||
| Book Value Per Share | 0.70 X | ||||
| Cash Flow From Operations | (699.69 K) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (0.69) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 231 | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 3.69 M | ||||
| Total Asset | 16.47 M | ||||
| Retained Earnings | (39.29 M) | ||||
| Working Capital | (823.73 K) | ||||
| Current Asset | 20.99 M | ||||
| Current Liabilities | 12.95 M | ||||
| Net Asset | 16.47 M |
About China Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Pharma Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China Pharma Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out China Pharma Piotroski F Score and China Pharma Altman Z Score analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.